|
1
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the surveillance, epidemiology, and end results program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marko TA, Diessner BJ and Spector LG:
Prevalence of metastasis at diagnosis of osteosarcoma: An
international comparison. Pediatr Blood Cancer. 63:1006–1011. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Duchman KR, Gao Y and Miller BJ:
Prognostic factors for survival in patients with high-grade
osteosarcoma using the Surveillance, Epidemiology, and End Results
(SEER) Program database. Cancer Epidemiol. 39:593–599. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kempf-Bielack B, Bielack SS, Jürgens H,
Branscheid D, Berdel WE, Exner GU, Göbel U, Helmke K, Jundt G,
Kabisch H, et al: Osteosarcoma relapse after combined modality
therapy: An analysis of unselected patients in the Cooperative
Osteosarcoma Study Group (COSS). J Clin Oncol. 23:559–568. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wu PK, Chen WM, Chen CF, Lee OK, Haung CK
and Chen TH: Primary osteogenic sarcoma with pulmonary metastasis:
Clinical results and prognostic factors in 91 patients. Jpn J Clin
Oncol. 39:514–522. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Goorin AM, Schwartzentruber DJ, Devidas M,
Gebhardt MC, Ayala AG, Harris MB, Helman LJ, Grier HE and Link MP:
Presurgical chemotherapy compared with immediate surgery and
adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric
oncology group study POG-8651. J Clin Oncol. 21:1574–1580. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Meyers PA, Heller G, Healey J, Huvos A,
Lane J, Marcove R, Applewhite A, Vlamis V and Rosen G: Chemotherapy
for nonmetastatic osteogenic sarcoma: The Memorial Sloan-Kettering
experience. J Clin Oncol. 10:5–15. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chou AJ, Kleinerman ES, Krailo MD, Chen Z,
Betcher DL, Healey JH, Conrad EU III, Nieder ML, Weiner MA, Wells
RJ, et al: Addition of muramyl tripeptide to chemotherapy for
patients with newly diagnosed metastatic osteosarcoma: A report
from the Children's Oncology Group. Cancer. 115:5339–5348. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bauskin AR, Brown DA, Kuffner T, Johnen H,
Luo XW, Hunter M and Breit SN: Role of macrophage inhibitory
cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res.
66:4983–4986. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brown DA, Breit SN, Buring J, Fairlie WD,
Bauskin AR, Liu T and Ridker PM: Concentration in plasma of
macrophage inhibitory cytokine-1 and risk of cardiovascular events
in women: A nested case-control study. Lancet. 359:2159–2163. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brown DA, Ward RL, Buckhaults P, Liu T,
Romans KE, Hawkins NJ, Bauskin AR, Kinzler KW, Vogelstein B and
Breit SN: MIC-1 serum level and genotype: Associations with
progress and prognosis of colorectal carcinoma. Clin Cancer Res.
9:2642–2650. 2003.PubMed/NCBI
|
|
12
|
Tamary H, Shalev H, Perez-Avraham G,
Zoldan M, Levi I, Swinkels DW, Tanno T and Miller JL: Elevated
growth differentiation factor 15 expression in patients with
congenital dyserythropoietic anemia type I. Blood. 112:5241–5244.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Staff AC, Trovik J, Eriksson AG, Wik E,
Wollert KC, Kempf T and Salvesen HB: Elevated plasma growth
differentiation factor-15 correlates with lymph node metastases and
poor survival in endometrial cancer. Clin Cancer Res. 17:4825–4833.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Blanco-Calvo M, Tarrío N, Reboredo M,
Haz-Conde M, García J, Quindós M, Figueroa A, Antón-Aparicio L,
Calvo L and Valladares-Ayerbes M: Circulating levels of GDF15, MMP7
and miR-200c as a poor prognostic signature in gastric cancer.
Future Oncol. 10:1187–1202. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Winand FJ, Boegemann M, Gallitz I, Hertle
L, Semjonow A, Eveslage M, Van Aken HK, Herrmann E and Steinbicker
AU: GDF15 and Hepcidin as prognostic factors in patients with
prostate cancer. J Mol Biomark Diagn. 5:1992014.
|
|
16
|
Enneking WF, Spanier SS and Goodman MA: A
system for the surgical staging of musculoskeletal sarcoma. Clin
Orthop Relat Res. 106–120. 1980.PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang X, Ling MT, Guan XY, Tsao SW, Cheung
HW, Lee DT and Wong YC: Identification of a novel function of
TWIST, a bHLH protein, in the development of acquired taxol
resistance in human cancer cells. Oncogene. 23:474–482. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kong KL, Kwong DL, Fu L, Chan TH, Chen L,
Liu H, Li Y, Zhu YH, Bi J, Qin YR, et al: Characterization of a
candidate tumor suppressor gene uroplakin 1A in esophageal squamous
cell carcinoma. Cancer Res. 70:8832–8841. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li Q, Ye L, Guo W, Wang M, Huang S and
Peng X: PHF21B overexpression promotes cancer stem cell-like traits
in prostate cancer cells by activating the Wnt/β-catenin signaling
pathway. J Exp Clin Cancer Res. 36:852017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Endo-Munoz L, Cumming A, Rickwood D,
Wilson D, Cueva C, Ng C, Strutton G, Cassady AI, Evdokiou A,
Sommerville S, et al: Loss of osteoclasts contributes to
development of osteosarcoma pulmonary metastases. Cancer Res.
70:7063–7072. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Böttner M, Suter-Crazzolara C, Schober A
and Unsicker K: Expression of a novel member of the TGF-beta
superfamily, growth/differentiation factor-15/macrophage-inhibiting
cytokine-1 (GDF-15/MIC-1) in adult rat tissues. Cell Tissue Res.
297:103–110. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sung JY, Park SY, Kim JH, Kang HG, Yoon
JH, Na YS, Kim YN and Park BK: Interferon consensus
sequence-binding protein (ICSBP) promotes epithelial-to-mesenchymal
transition (EMT)-like phenomena, cell-motility, and invasion via
TGF-β signaling in U2OS cells. Cell Death Dis. 5:e12242014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kager L, Zoubek A, Pötschger U, Kastner U,
Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M,
Winkelmann W, et al: Primary metastatic osteosarcoma: Presentation
and outcome of patients treated on neoadjuvant Cooperative
Osteosarcoma Study Group protocols. J Clin Oncol. 21:2011–2018.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Geller DS and Gorlick R: Osteosarcoma: A
review of diagnosis, management, and treatment strategies. Clin Adv
Hematol Oncol. 8:705–718. 2010.PubMed/NCBI
|
|
26
|
Koopmann J, Buckhaults P, Brown DA,
Zahurak ML, Sato N, Fukushima N, Sokoll LJ, Chan DW, Yeo CJ, Hruban
RH, et al: Serum macrophage inhibitory cytokine 1 as a marker of
pancreatic and other periampullary cancers. Clin Cancer Res.
10:2386–2392. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Suesskind D, Schatz A, Schnichels S,
Coupland SE, Lake SL, Wissinger B, Bartz-Schmidt KU and Henke-Fahle
S: GDF-15: A novel serum marker for metastases in uveal melanoma
patients. Graefes Arch Clin Exp Ophthalmol. 250:887–895. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li PX, Wong J, Ayed A, Ngo D, Brade AM,
Arrowsmith C, Austin RC and Klamut HJ: Placental transforming
growth factor-beta is a downstream mediator of the growth arrest
and apoptotic response of tumor cells to DNA damage and p53
overexpression. J Biol Chem. 275:20127–20135. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Baek SJ, Kim KS, Nixon JB, Wilson LC and
Eling TE: Cyclooxygenase inhibitors regulate the expression of a
TGF-beta superfamily member that has proapoptotic and
antitumorigenic activities. Mol Pharmacol. 59:901–908. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Albertoni M, Shaw PH, Nozaki M, Godard S,
Tenan M, Hamou MF, Fairlie DW, Breit SN, Paralkar VM, de Tribolet
N, et al: Anoxia induces macrophage inhibitory cytokine-1 (MIC-1)
in glioblastoma cells independently of p53 and HIF-1. Oncogene.
21:4212–4219. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee DH, Yang Y, Lee SJ, Kim KY, Koo TH,
Shin SM, Song KS, Lee YH, Kim YJ, Lee JJ, et al: Macrophage
inhibitory cytokine-1 induces the invasiveness of gastric cancer
cells by up-regulating the urokinase-type plasminogen activator
system. Cancer Res. 63:4648–4655. 2003.PubMed/NCBI
|
|
32
|
Liu T, Bauskin AR, Zaunders J, Brown DA,
Pankhurst S, Russell PJ and Breit SN: Macrophage inhibitory
cytokine 1 reduces cell adhesion and induces apoptosis in prostate
cancer cells. Cancer Res. 63:5034–5040. 2003.PubMed/NCBI
|
